Antipsychotics and Mortality: Adjusting for Mortality Risk Scores to Address Confounding by Terminal Illness

By  

JOURNAL OF AMERICAN GERIATRICS SOCIETY, Vol. 63, Iss. 3, 2015-03 ,pp. : 516-523

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK**

By Davies Andrew   Vardeva Kawitha   Loze Jean-Yves   L’’Italien Gilbert J.   Sennfalt Karin   Baardewijk Marc van  

Current Medical Research and Opinion, Vol. 24, Iss. 11, 2008-11 ,pp. : 3275-3285

Informa Healthcare

Access to resources Recommend Favorite

Are exposure to cytomegalovirus and genetic variation on chromosome 6p joint risk factors for schizophrenia?

By Kim Jung Jin   Shirts Brian H.   Dayal Madhulika   Bacanu Silviu-alin   Wood Joel   Xie Weiting   Zhang Xiaohua   Chowdari Kodavali V.   Yolken Robert   Devlin Bernie   Nimgaonkar Vishwajit L.  

Annals of Medicine, Vol. 39, Iss. 2, 2007-01 ,pp. : 145-153

Informa Healthcare

Access to resources Recommend Favorite

Rivastigmine treatment as an add-on to antipsychotics in patients with schizophrenia and cognitive deficits

By Chouinard Sylvie   Stip Emmanuel   Poulin Julie   Melun Jean-Pierre   Godbout Roger   Guillem François   Cohen Henri  

Current Medical Research and Opinion, Vol. 23, Iss. 3, 2007-03 ,pp. : 575-583

Informa Healthcare

Access to resources Recommend Favorite

One-year clinical and economic consequences of oral atypical antipsychotics in the treatment of schizophrenia*

By Edwards Natalie C.   Pesa Jacqueline   Meletiche Dennis M.   Engelhart Luella   Thompson Ann K.   Sherr Jay   Dirani Riad  

Current Medical Research and Opinion, Vol. 24, Iss. 12, 2008-12 ,pp. : 3341-3355

Informa Healthcare

Access to resources Recommend Favorite